Shares of TiGenix (NASDAQ:TIG) have been assigned an average broker rating score of 2.50 (Hold) from the four analysts that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.
Brokerages have set a twelve-month consensus target price of $36.40 for the company, according to Zacks. Zacks has also assigned TiGenix an industry rank of 150 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut TiGenix from a “buy” rating to a “hold” rating in a research report on Thursday, January 25th.
TiGenix traded down $0.23, hitting $41.30, during trading hours on Monday, Marketbeat Ratings reports. 60 shares of the stock traded hands, compared to its average volume of 4,584. The company has a quick ratio of 0.69, a current ratio of 0.71 and a debt-to-equity ratio of 0.24. TiGenix has a one year low of $16.70 and a one year high of $48.00.
An institutional investor recently bought a new position in TiGenix stock. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of TiGenix (NASDAQ:TIG) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 4,965 shares of the company’s stock, valued at approximately $214,000. 4.42% of the stock is owned by institutional investors and hedge funds.
TiGenix Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Get a free copy of the Zacks research report on TiGenix (TIG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TiGenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix and related companies with MarketBeat.com's FREE daily email newsletter.